Art. -Nr.: HY-13541

ADH-1

Name: ADH-1
Brand: MedChemExpress
SKU: HY-13541
Price: 110.00 USD
Availability: InStock
Rating: 5 (12 reviews)

(Synonyms: Exherin)

12 Cited Publications

Kundenbewertung

Based on 12 publication(s) in Google Scholar

ADH-1 (Exherin) is a cyclic pentapeptide N-cadherin antagonist. ADH-1 binds to N-cadherin EC1-2 as an HAV mimetic, competitively blocks homophilic trans interactions, forms a stable protein-drug complex, and induces conformational rearrangement. ADH-1 targets tumor microvasculature, causing vascular injury and apoptosis. ADH-1 inhibits tumor growth and metastasis in mouse tumor models. ADH-1 can be used in cancer-related research.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 99.74%
CAS. Nr.: 229971-81-7
Formel: C₂₂H₃₄N₈O₆S₂
Molecular Weight:570.69

Speicherung:

Sealed storage, away from moisture.

Powder -80°C, 2 years , -20°C, 1 year

* The compound is unstable in solutions, freshly prepared is recommended.

ADH-1 Chemical Structure

CAS. Nr.: 229971-81-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (12)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

In Vitro

Anti-cancerApoptosisOthers

Anti-cancer

Apoptosis

ADH-1 is a cyclic pentapeptide vascular targeting agent that competitively inhibits N-cadherin-mediated cell interactions, inducing tumor vascular dissolution and apoptosis^[1].

Others

ADH-1 directly binds recombinant human N-cadherin EC1-2mut, with the most probable unbinding force of 295 pN and a k_off of 14.6 s^-1^[3].
ADH-1 reduces the homophilic trans-dissociation frequency of N-cadherin EC1-2mut from 41.1% to 11.6%, inhibiting N-cadherin-N-cadherin interactions^[3].
ADH-1 binds N-cadherin EC1-2mut and alters the microenvironment around aromatic amino acids, reaching binding equilibrium at 175 s^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Anti-cancerLocal Vascular Regulation

Anti-cancer

Local Vascular Regulation

ADH-1 produces rapid tumour vascular damage and inhibits tumour growth in murine carcinoma models^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Related Protocols :

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991			2011-05	PHASE1

Chemical Information

CAS. Nr. 229971-81-7
Appearance Solid
Molecular Weight 570.69
Formel C₂₂H₃₄N₈O₆S₂
Color White to off-white
Synonyms

Exherin
Sequence

Cys-His-Ala-Val-Cys
Sequence Shortening

CHAVC
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

* The compound is unstable in solutions, freshly prepared is recommended.

Publications (12)

All Cell Proliferation/Viability AssayIn Vivo Efficacy StudyWB

Sort by:

Journal Impact Factor

Cell Death Dis

Co-loaded lapatinib/PAB by ferritin nanoparticles eliminated ECM-detached cluster cells via modulating EGFR in triple-negative breast cancer. [Abstract]

2022 Jun 20;13(6):557. PMID: 35725558
Mol Ther

2026 Sep 25:S1525-0016(26)00799-9. PMID: 42798181
Oncogene

Distinct roles of treatment schemes and BRCA2 on the restoration of homologous recombination DNA repair and PARP inhibitor resistance in ovarian cancer. [Abstract]

2022 Nov;41(46):5020-5031. PMID: 36224341

ADH-1 purchased from MedChemExpress. Usage Cited in: Oncogene. 2022 Nov;41(46):5020-5031. [Abstract]

Cell growth was examined by XTT assay. Cells were treated with olaparib and/or N-cadherin inhibitor (ADH-1, 0-100 μM) at indicated doses for 72 hours.
Sci Rep

The RGD motif is involved in CD97/ADGRE5-promoted cell adhesion and viability of HT1080 cells. [Abstract]

2019 Feb 6;9(1):1517. PMID: 30728423
J Cell Mol Med

Telmisartan anti-cancer activities mechanism through targeting N-cadherin by mimicking ADH-1 function. [Abstract]

2022 Apr;26(8):2392-2403. PMID: 35224849
iScience

Dendritic cells overcome Cre/Lox induced gene deficiency by siphoning cytosolic material from surrounding cells. [Abstract]

2024 Feb 6;27(3):109119. PMID: 38384841
J Pain Res

Spinal N-Cadherin/CREB Signaling Contributes to Chronic Alcohol Consumption-Enhanced Postsurgical Pain. [Abstract]

2020 Aug 12:13:2065-2072. PMID: 32848450

ADH-1 purchased from MedChemExpress. Usage Cited in: J Pain Res. 2020 Aug 12:13:2065-2072. [Abstract]

On day 20 after plantar incision and 5-week ethanol consumption, intrathecal injection of ADH-1 (40 μg), a specific N-cadherin inhibitor, significantly increased the decreased paw withdrawal threshold on the ipsilateral side compared to the vehicle control group.

ADH-1 purchased from MedChemExpress. Usage Cited in: J Pain Res. 2020 Aug 12:13:2065-2072. [Abstract]

On day 20 after plantar incision and 5-week ethanol consumption, intrathecal injection of ADH-1 (40 μg). The ADH-1 treatment had no effect on the paw withdrawal threshold on the contralateral side.
Biochem Biophys Res Commun

The role of the RGD motif in CD97/ADGRE5-and EMR2/ADGRE2-modulated tumor angiogenesis. [Abstract]

2019 Dec 3;520(2):243-249. PMID: 31594642

ADH-1 purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2019 Dec 3;520(2):243-249. [Abstract]

HT1080 stable cells were cultured in the absence or presence of exherin (ADH-1, 100 μg/mL), and the level of MMP-9 was evaluated by MMP zymography.
University of Delaware

2026.
bioRxiv

2025 Oct 3.
bioRxiv

2025 Oct 24.
bioRxiv

Dendritic Cells Overcome Cre/Lox Induced Gene Deficiency by Siphoning Material From Neighboring Cells Using Intracellular Monitoring-a Novel Mechanism of Antigen Acquisition. [Abstract]

2023 Jul 25:2023.07.22.550169. PMID: 37546718

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (175.23 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.7523 mL

8.7613 mL

17.5226 mL

5 mM

0.3505 mL

1.7523 mL

3.5045 mL

10 mM

0.1752 mL

0.8761 mL

1.7523 mL

Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (3.64 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (3.64 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (3.64 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 20 mg/mL (35.05 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (301 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Jonker D J, et al. A phase I study of the novel molecularly targeted vascular targeting agent, Exherin (ADH-1), shows activity in some patients with refractory solid tumors stratified according to N-cadherin expression. J Clin Oncol, 2005, 23(16_suppl):3038.

[2]. Perotti A, et al. Clinical and pharmacological phase I evaluation of ExherinTM (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours. Annals of Oncology, 2009, 20(4):741-745.

[3]. Biswas J, et al. Modulation of N-cadherin-mediated homophilic trans interaction upon direct binding of ADH-1: Exploring the molecular basis of action of ADH-1 as N-cadherin inhibitor. Biochimie. 2026 Oct;249:141-149. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.7523 mL	8.7613 mL	17.5226 mL	43.8066 mL
	5 mM	0.3505 mL	1.7523 mL	3.5045 mL	8.7613 mL
	10 mM	0.1752 mL	0.8761 mL	1.7523 mL	4.3807 mL
	15 mM	0.1168 mL	0.5841 mL	1.1682 mL	2.9204 mL
	20 mM	0.0876 mL	0.4381 mL	0.8761 mL	2.1903 mL
	25 mM	0.0701 mL	0.3505 mL	0.7009 mL	1.7523 mL
	30 mM	0.0584 mL	0.2920 mL	0.5841 mL	1.4602 mL
	40 mM	0.0438 mL	0.2190 mL	0.4381 mL	1.0952 mL
	50 mM	0.0350 mL	0.1752 mL	0.3505 mL	0.8761 mL
	60 mM	0.0292 mL	0.1460 mL	0.2920 mL	0.7301 mL
	80 mM	0.0219 mL	0.1095 mL	0.2190 mL	0.5476 mL
	100 mM	0.0175 mL	0.0876 mL	0.1752 mL	0.4381 mL

Bioz

ADH-1

12 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

ADH-1

Publications Citing Use of MedChemExpress (MCE) ADH-1